(IMVT) Immunovant - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45258J1025

Stock: Monoclonal Antibodies, Autoimmune Diseases, Clinical-Stage, Immunotherapy

Total Rating 34
Risk 32
Buy Signal -1.15
Biotechnology » Biotechnology
Age: 6.6y
Market Cap: 5,238m
Avg Trading Vol: 38.7M USD
ATR: 4.57%
Peers RS (IBD): 43.50

EPS (Earnings per Share)

EPS (Earnings per Share) of IMVT over the last years for every Quarter: "2020-12": -0.32, "2021-03": -0.29, "2021-06": -0.31, "2021-09": -0.35, "2021-12": -0.36, "2022-03": -0.41, "2022-06": -0.35, "2022-09": -0.41, "2022-12": -0.49, "2023-03": -0.46, "2023-06": -0.57, "2023-09": -0.45, "2023-12": -0.36, "2024-03": -0.52, "2024-06": -0.6, "2024-09": -0.74, "2024-12": -0.76, "2025-03": -0.64, "2025-06": -0.71, "2025-09": -0.73, "2025-12": 0,
EPS CAGR: 20.68%
EPS Trend: -21.5%
Last SUE: 4.00
Qual. Beats: 1

Revenue

Revenue of IMVT over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 1.5, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0.16, 2025-06: 0, 2025-09: 0, 2025-12: null,
Rev. CAGR: 0.00%
Rev. Trend: 12.5%
Last SUE: 0.00
Qual. Beats: 0
Risk 5d forecast
Volatility 57.0%
Relative Tail Risk -11.0%
Reward TTM
Sharpe Ratio 0.33
Alpha 0.99
Character TTM
Beta 1.015
Beta Downside 0.932
Drawdowns 3y
Max DD 69.88%
CAGR/Max DD 0.13

Description: IMVT Immunovant January 12, 2026

Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biotechnology firm focused on developing monoclonal antibodies that modulate the immune system for a range of autoimmune indications.

The company’s lead programs are IMVT-1402, a B-cell-targeting antibody being evaluated in Graves’ disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), cutaneous lupus erythematosus, and Sjögren’s syndrome; and batoclimab, a complement-C5 inhibitor pursued in myasthenia gravis, CIDP, and thyroid eye disease.

As of the most recent 10-Q, Immunovant reported cash and cash equivalents of roughly $115 million, providing an estimated runway of 12–15 months at current burn rates, and its market capitalization hovers near $300 million.

The autoimmune-therapeutics market is projected to grow at a CAGR of ~7 % through 2030, driven by rising prevalence of chronic inflammatory diseases and expanding payer willingness to cover biologics that offer steroid-sparing benefits.

For a deeper, data-rich look at IMVT’s valuation metrics and risk profile, you might explore the analyst tools on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: -464.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.74 > 0.02 and ΔFCF/TA -21.19 > 1.0
NWC/Revenue: 318.9k% < 20% (prev 29.4k%; Δ 289.6k% < -1%)
CFO/TA -0.74 > 3% & CFO -431.0m > Net Income -464.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 9.07 > 1.5 & < 3
Outstanding Shares: last quarter (173.6m) vs 12m ago 18.55% < -2%
Gross Margin: -78.75% > 18% (prev 0.81%; Δ -7956 % > 0.5%)
Asset Turnover: 0.03% > 50% (prev 0.29%; Δ -0.26% > 0%)
Interest Coverage Ratio: -19.75 > 6 (EBITDA TTM -486.7m / Interest Expense TTM -24.7m)

Altman Z'' -15.00

A: 0.88 (Total Current Assets 573.5m - Total Current Liabilities 63.3m) / Total Assets 583.0m
B: -2.55 (Retained Earnings -1.49b / Total Assets 583.0m)
C: -0.89 (EBIT TTM -487.1m / Avg Total Assets 549.3m)
D: -23.48 (Book Value of Equity -1.49b / Total Liabilities 63.3m)
Altman-Z'' Score: -33.18 = D

Beneish M 1.00

DSRI: 9.84 (Receivables 1.97m/1.88m, Revenue 160.0k/1.50m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.02 (AQ_t 0.02 / AQ_t-1 0.01)
SGI: 0.11 (Revenue 160.0k / 1.50m)
TATA: -0.06 (NI -464.7m - CFO -431.0m) / TA 583.0m)
Beneish M-Score: 3.56 (Cap -4..+1) = D

What is the price of IMVT shares?

As of February 06, 2026, the stock is trading at USD 24.06 with a total of 2,087,587 shares traded.
Over the past week, the price has changed by -9.04%, over one month by -3.64%, over three months by +1.95% and over the past year by +6.89%.

Is IMVT a buy, sell or hold?

Immunovant has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy IMVT.
  • StrongBuy: 10
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the IMVT price?

Issuer Target Up/Down from current
Wallstreet Target Price 40.3 67.5%
Analysts Target Price 40.3 67.5%
ValueRay Target Price 25.3 5%

IMVT Fundamental Data Overview February 03, 2026

P/B = 10.254
Revenue TTM = 160.0k USD
EBIT TTM = -487.1m USD
EBITDA TTM = -486.7m USD
Long Term Debt = 98.0k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 98.0k USD (from shortTermDebt, last fiscal year)
Debt = 98.0k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -521.9m USD (from netDebt column, last quarter)
Enterprise Value = 4.72b USD (5.24b + Debt 98.0k - CCE 521.9m)
Interest Coverage Ratio = -19.75 (Ebit TTM -487.1m / Interest Expense TTM -24.7m)
EV/FCF = -10.93x (Enterprise Value 4.72b / FCF TTM -431.3m)
FCF Yield = -9.15% (FCF TTM -431.3m / Enterprise Value 4.72b)
FCF Margin = -269.6k% (FCF TTM -431.3m / Revenue TTM 160.0k)
Net Margin = -290.4k% (Net Income TTM -464.7m / Revenue TTM 160.0k)
Gross Margin = -78.75% ((Revenue TTM 160.0k - Cost of Revenue TTM 286.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 8.09 (Enterprise Value 4.72b / Total Assets 583.0m)
Interest Expense / Debt = 4148 % (Interest Expense 4.07m / Debt 98.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -384.8m (EBIT -487.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.07 (Total Current Assets 573.5m / Total Current Liabilities 63.3m)
Debt / Equity = 0.00 (Debt 98.0k / totalStockholderEquity, last quarter 519.7m)
Debt / EBITDA = 1.07 (negative EBITDA) (Net Debt -521.9m / EBITDA -486.7m)
Debt / FCF = 1.21 (negative FCF - burning cash) (Net Debt -521.9m / FCF TTM -431.3m)
Total Stockholder Equity = 547.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -84.59% (Net Income -464.7m / Total Assets 583.0m)
RoE = -84.94% (Net Income TTM -464.7m / Total Stockholder Equity 547.1m)
RoCE = -89.02% (EBIT -487.1m / Capital Employed (Equity 547.1m + L.T.Debt 98.0k))
RoIC = -70.34% (negative operating profit) (NOPAT -384.8m / Invested Capital 547.1m)
WACC = 9.65% (E(5.24b)/V(5.24b) * Re(9.65%) + (debt cost/tax rate unavailable))
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.61%
Fair Price DCF = unknown (Cash Flow -431.3m)
EPS Correlation: -21.54 | EPS CAGR: 20.68% | SUE: 4.0 | # QB: 1
Revenue Correlation: 12.51 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Year (2027-03-31): EPS=-3.00 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-2.5% | Growth Revenue=+0.0%

Additional Sources for IMVT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle